Calcineurin inhibitors in renal transplantation still needed but in reduced doses: A review

Transplantation Proceedings

Volumn 42, Issue 6, 2010, Pages 2205-2208

  Ponticelli, C ^a   Scolari, M P ^b  

^a Scientific Institute Humanitas   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CALCINEURIN; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY-BASED DRUG WITHDRAWALS; SIROLIMUS;

EID: 77955539030     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.05.036     Document Type: Conference Paper

References (22)

1. J. Moore, L. Middleton, and P. Cockwell Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis Transplantation 87 2009 591
2. T.R. Srinivas, J.D. Schold, and G. Guerra Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation Am J Transplant 7 2007 586
3. S.M. Flechner, D. Goldfarb, and K. Solez Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs Transplantation 83 2007 883
4. H. Ekberg, H. Tedesco-Silva, and A. Demirbas Reduced exposure to calcineurin inhibitors in renal transplantation N Engl J Med 357 2007 2562
5. P.J. Smak Gregoor, R.G. de Svaux, and G. Ligtenberg Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study J Am Soc Nephrol 13 2002 1365
6. D. Abramowicz, M. Del Carmen Rial, and S. Vitko Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study J Am Soc Nephrol 16 2005 2234
7. H. Ekberg, J. Griny, and B. Nashan Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study Am J Transplant 7 2007 560
8. R. Oberbauer, G. Segoloni, J.M. Campistol Rapamune Maintenance Regimen Study Group Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation Transpl Int 18 2005 22
9. F.S. Shihab, W.M. Bennett, and H. Yi Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity Am J Nephrol 26 2006 400
10. Y. Lebranchu, A. Thierry, and O. Toupance Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study Am J Transplant 9 2009 1115
11. G. Opelz, and B. Dohler Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant Transplantation 86 2008 371
12. F.P. Schena, M.D. Pascoe, and J. Alberúu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
13. D. Abramowicz, K. Hadaya, and M. Hazzan Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects Nephrol Dial Transplant 23 2008 3727
14. J.M. Griny, and J.M. Cruzado Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress Am J Transplant 9 2009 2447
15. S. Bunnapradist, K.L. Lentine, and T.E. Burroughs Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure Transplantation 82 2006 102
16. K. Rupprecht, C. Schmidt, and A. Rasp Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers J Clin Pharmacol 49 2009 1196
17. A. Sánchez-Fructuoso, J.C. Ruiz, and M. Rengel Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study Transplant Proc 41 2009 2309
18. M. Cooper, K.L. Deering, and D.P. Slakey Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients Transplantation 88 2009 514
19. J.M. Kovarik, J.J. Curtis, and D.E. Hricik Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus Transplant Proc 38 2006 3456
20. B. Nashan, J. Curtis, and C. Ponticelli Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study Transplantation 78 2004 1332
21. H. Tedesco-Silva Jr, S. Vitko, and J. Pascual 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients Transpl Int 20 2007 27
22. M. Salvadori, M.P. Scolari, and E. Bertoni Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial Transplantation 88 2009 1194